Search results
5 FDA decisions to watch in the third quarter
BioPharma Dive· 3 days agoMultibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach...
New gene editing tool to cure rare disorders | Hyderabad News - Times of India
The Times of India· 3 days agoand Industrial Research - Institute of Genomics and Integrative Biology (CSIR-IGIB) in New Delhi and the LV Prasad Eye Institute (LVPEI ...
Sirnaomics concludes Phase I trial of pancreatic cancer treatment
Clinical Trials Arena· 5 days agoIt was designed to assess the safety, tolerability, and anti-tumour activity of STP707, using...
The state of oligonucleotide therapeutic manufacturing: what biopharmaceutical players need to know
Pharmaceutical Technology· 4 days agoIn the genomic medicine toolbox, oligonucleotide therapeutics offer highly specific and effective ...
Johnson & Johnson reports data from Phase III multiple myeloma treatment trial
Clinical Trials Arena· 3 days agoThe randomised study is designed to assess the efficacy and safety of CARVYKTI against...
FDA approves a second Alzheimer's drug that can modestly slow disease - CNBC TV18
CNBC TV18· 2 days agoU.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing...
Rare and fatal brain-eating amoeba infection | Explained
The Hindu· 1 day agoA12-year-old boy, E.P. Mridul, from Feroke in Kozhikode district of Kerala, who had been undergoing ...
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
BioPharma Dive· 5 days agoLike many of its cell therapy peers, Artiva, which originally sought an IPO in 2021, has shifted its...
Eli Lilly Alzheimer's drug approved by US FDA - ET HealthWorld | Pharma
The Economic Times· 3 days agoLondon: The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's treatment for early...
Healthy at Every Size? Here's What Doctors Look for Beyond BMI
Verywell Health· 2 days agoPeople with chronic diseases, in particular, shouldn't place too much importance on BMI, Gitomer...